468 related articles for article (PubMed ID: 26449414)
1. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants.
Ansell JE
J Thromb Thrombolysis; 2016 Feb; 41(2):248-52. PubMed ID: 26449414
[TBL] [Abstract][Full Text] [Related]
2. Reversal of direct oral anticoagulants: a practical approach.
Shih AW; Crowther MA
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
[TBL] [Abstract][Full Text] [Related]
3. How can we reverse bleeding in patients on direct oral anticoagulants?
Crowther M; Cuker A
Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
[TBL] [Abstract][Full Text] [Related]
4. Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options.
Ansell JE
Am J Cardiovasc Drugs; 2016 Jun; 16(3):163-70. PubMed ID: 26872887
[TBL] [Abstract][Full Text] [Related]
5. Who, when, and how to reverse non-vitamin K oral anticoagulants.
Aronis KN; Hylek EM
J Thromb Thrombolysis; 2016 Feb; 41(2):253-72. PubMed ID: 26627486
[TBL] [Abstract][Full Text] [Related]
6. Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.
Huisman MV; Fanikos J
Am J Med; 2016 Nov; 129(11S):S89-S96. PubMed ID: 27569673
[TBL] [Abstract][Full Text] [Related]
7. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors.
Nafee T; Aslam A; Chi G; Pahlavani S; Nimri D; Kuchkuntla AR; Talib U; Michalak N; Daaboul Y; Korjian S; Gallo A; Gibson CM
Expert Rev Cardiovasc Ther; 2017 Apr; 15(4):237-245. PubMed ID: 28282497
[TBL] [Abstract][Full Text] [Related]
8. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
[TBL] [Abstract][Full Text] [Related]
9. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
Tummala R; Kavtaradze A; Gupta A; Ghosh RK
Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
[TBL] [Abstract][Full Text] [Related]
10. Antidotes for reversal of direct oral anticoagulants.
Dobesh PP; Bhatt SH; Trujillo TC; Glaubius K
Pharmacol Ther; 2019 Dec; 204():107405. PubMed ID: 31521696
[TBL] [Abstract][Full Text] [Related]
11. Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs).
Hussain SS; Tyroch AH; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):76-81. PubMed ID: 27215215
[TBL] [Abstract][Full Text] [Related]
12. When and How to Use Reversal Agents for Direct Oral Anticoagulants?
Gómez-Outes A; Suárez-Gea ML; Lecumberri R
Curr Cardiol Rep; 2023 May; 25(5):371-380. PubMed ID: 36976497
[TBL] [Abstract][Full Text] [Related]
13. Reversal agents for non-vitamin K antagonist oral anticoagulants.
Levy JH; Douketis J; Weitz JI
Nat Rev Cardiol; 2018 May; 15(5):273-281. PubMed ID: 29345686
[TBL] [Abstract][Full Text] [Related]
14. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab.
Hu TY; Vaidya VR; Asirvatham SJ
Vasc Health Risk Manag; 2016; 12():35-44. PubMed ID: 26937198
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
Levy JH
Am J Med; 2016 Nov; 129(11S):S47-S53. PubMed ID: 27569675
[TBL] [Abstract][Full Text] [Related]
16. Oral anticoagulants and status of antidotes for the reversal of bleeding risk.
Ebright J; Mousa SA
Clin Appl Thromb Hemost; 2015 Mar; 21(2):105-14. PubMed ID: 25115762
[TBL] [Abstract][Full Text] [Related]
17. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
Kaide CG; Gulseth MP
J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
[TBL] [Abstract][Full Text] [Related]
18. Reversal of direct oral anticoagulants.
Almegren M
Vasc Health Risk Manag; 2017; 13():287-292. PubMed ID: 28769570
[TBL] [Abstract][Full Text] [Related]
19. Reversal agents for use with direct and indirect anticoagulants.
Smythe MA; Trujillo T; Fanikos J
Am J Health Syst Pharm; 2016 May; 73(10 Suppl 2):S27-48. PubMed ID: 27147456
[TBL] [Abstract][Full Text] [Related]
20. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
Desai NR; Cornutt D
Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
